INMB
What one share of Inmune Bio holds
Biological Products, (No Diagnostic Substances)
Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to
Inmune Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.69 |
|---|---|
| Cash and investments | $0.67 |
| Debt | $0.54 |
| Book value | $0.74 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $0.00 | −$0.13 | — | −$0.12 | — | $2.18 |
| 2018 | $0.00 | −$1.43 | — | −$0.24 | — | $1.90 |
| 2019 | — | −$0.75 | — | −$0.52 | — | $2.19 |
| 2020 | $0.00 | −$1.01 | — | −$0.75 | — | $2.87 |
| 2021 | $0.01 | −$1.88 | — | −$1.77 | — | $4.50 |
| 2022 | $0.02 | −$1.52 | — | −$1.27 | — | $3.35 |
| 2023 | $0.01 | −$1.67 | — | −$0.67 | — | $2.08 |
| 2024 | $0.00 | −$2.11 | — | −$1.67 | — | $1.44 |
| 2025 | $0.00 | −$1.86 | $0.04 | −$0.95 | — | $0.88 |